Looking for volunteers
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated 16 Aug 2022
- What is being tested
- ADT; Abiraterone Acetate; Prednisolone tablets; Enzalutamide; Apalutamide; Darotamide; Rezvilutamide; PARP inhibitor; Robot-assisted radical prostatectomy
- For
- Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer; Intense Endocrine Therapy
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years to 80 years. About 900 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 1 Feb 2020, ends 30 June 2030. Registered 7 June 2022.
- Results
- None posted yet.
In the researchers' words
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Sites
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing UniversityNanjing, Jiangsu, China